Documente Academic
Documente Profesional
Documente Cultură
April 2011
Table of contents
Designed for consumers Scientific evidence Regulatory status Technological data Marketing potential Conclusion
What is Chromax?
A newly-approved safe ingredient for effective weight management promotion
Chromax is a patented salt of trivalent chromium (Cr3+) and tri-picolinic acid, also known as chromium picolinate, containing 12% of pure chromium Chromax is the purest chromium picolinate on the market recognized as a quality reference. As a safe product and a source of bioavailable chromium, Chromax made the proof of its efficiency though numerous clinical studies
Chromax is the only chromium picolinate approved by the EU. Its high purity and safety testing makes it superior to other chromium products on the market.
4
The National Toxicology Program (USA) conducted safety studies, using purified chromium picolinate, which confirmed the long-term high dose safety of the pure chromium picolinate compound. (Rhodes et al, 2004, Stout et al, 2009)
The safety studies were repeated and resulted in clear demonstration of the safety of Chromax. (See Gudi et al, 2005; Slesinski et al, 2005).
Chromax chromium picolinate have the benefit of knowing that this is the form of chromium picolinate used as a standard for approval and is also the product used in safety and efficacy studies submitted to Regulatory authorities When purchasing Chromax chromium picolinate, the industry is assured of using chromium picolinate that meets and exceeds the EU standards Customers are better protected from lower quality products claiming to be high purity chromium picolinate since compound purity testing is required
Chromax is the quality reference on the market and insured a high safety contrary other products
Chromax:
On the weight management market, consumers are often eager to find more reliable solutions . Indeed, they often need to choose between safety or efficacy : When they choose Chromax, consumers are ensured have both a safe and efficient weight management solution.
7
Scientific evidence
Scientific evidence
Scientific evidence
10
Scientific evidence
* p<0.05
2000
* p<0.05
1500
1000
500
Chromium polynicotinate
Chromax
Chromax is significantly more abundant in urine than chromium nicotinate and chromium chloride, which indirectly shows that chromium picolinate is more absorbed
11
Scientific evidence
These studies demonstrate a significant difference in chromium bioavailability between Chromax and other sources of chromium
12
Scientific evidence
Enhancement in Insulin Sensitivity in Healthy Volunteers following supplementation with Chromium Picolinate. Morris et al, 1998
Volunteers: 6 healthy subjects Duration: 10 weeks Dosage: 1.6 mg/day of Chromax, equivalent to 200 g/day of pure chromium Results: Significant increase of fasting levels of plasma chromium during the 5 first weeks Fasting Blood glucose levels tends to decrease during the supplementation
13
Scientific evidence
Enhancement in Insulin Sensitivity in Healthy Volunteers following supplementation with Chromium Picolinate. Morris et al, 1998
3.0
2.5
*
2.0
* ** ** ** ** **
1.5
1.0
0.5
0.0
PreCr 1 2 3 4 5 6 7 8 9 10 Off 1 Off 2
Weeks
Chromax significantly reduces Insulin-Resistance at the dosage of 1.6 mg/day Chromax Significantly decrease fasting Insulin at the dosage of 1.6 mg/day
14
Scientific evidence
Volunteers 10 with PCOS(3) 50 type 2 diabetics with medication 180 type 2 diabetics with medication 162 type 1 and 2 diabetics with med. 11 type 2 diabetics with medication
Dosage(1) 1.6 mg (200 g) 1.6 mg (200 g) 1.6 mg (200 g) and 8.3 mg (1000 g)
Results glucose tolerance glycated hemoglobin(2) (*p<0.05) fasting glycemia (***p<0.001) glycated hemoglobin(2) (*p<0.05) fasting glycemia (*p<0.05) insulin production (*p<0.05) insulin sensitivity (***p<0.001) glycated hemoglobin(2) (*p<0.05)
of Chromax / day (equivalent dosage of pure chromium / day) glycated hemoglobin (HbA1c) is the reference biological marker for glycemia monitoring in diabetic patients PCOS = polycystic ovary syndrome, which is strongly correlated with insulin resistance and diabetes
In other dosages, more than 15 studies were conducted on Chromax to prove this effect.
15
Scientific evidence
16
Scientific evidence
STUDY 2
Volunteers: 31 football players Activity: weight-training 1 hour/day Duration: 6 weeks Dosage: 1.6 mg/day of Chromax, equivalent to 200 g/day of chromium Results: Significantly increase of lean body mass (p=0.031) Significant decrease in the total fat (p=0.001)
kg
***
*p<0.05 ***p<0.005
17
Scientific evidence
18
Scientific evidence
**
***
*
Placebo
* *** ***
1.6 mg/day of Chromax 3.3 mg/day of Chromax
BCI (Body Composition Index) = net difference between lean mass gain and fat mass loss
19
Scientific evidence
Chromax shows significant results on weight and fat mass loss while preserving lean mass, from the dosage of 2 mg/day
20
10
Scientific evidence
Volunteers: 42 women Inclusion criteria: BMI 25-40, reporting intense carb craving Duration: 8 weeks Dosage: 8.3 mg/day of equivalent to 1 000 g/day of pure chromium Chromax,
21
Chromax:
Scientific evidence
4. Exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. Docherty et al., 2005.
0 2 weeks 4 weeks 6 weeks 8 weeks
Volunteers: 75 mixed volunteers Inclusion criteria: experiencing atypical depression Duration: 8 weeks Dosage: 5 mg/day of Chromax, equivalent to 600 g/day of pure chromium
1.5
Score
Chromax significantly decreases hunger and carb craving from the dosage of 5 mg/day
22
11
Scientific evidence
Chromax has clinically proven efficacy on the regulation of carbohydrate metabolism at the dosage of 2 mg/day Chromax is a safe and effective ingredient for success in your weight management products
23
Regulatory status
12
Regulatory status
Asia: Authorized for use in food supplements in most countries: Australia, Indonesia, Malaysia, Singapore, Taiwan, Thailand, Authorized for use in functional foods in most countries: Indonesia, Singapore, Taiwan, Thailand, 25
Regulatory status
A clear label
Suggested labeling: Chromium picolinate ( Picolinate de chrome )
Chromax benefits from our regulatory expertise. Please feel free to contact us for further information.
26
13
Technological data
Technological data
Chromax - Purity
Analytical comparison of marketed chromium compounds Chromium #1 (multiple compounds) Chromax
(pure chromium picolinate)
28
14
Technological data
Chromax is a fine and homogeneous powder. It is red colored, water-soluble and pH-stable. Thanks to its high density and to its low dosage (2 mg/day), Chromax can easily be implemented into various matrices: Food supplements: tablets, capsules, softgels, gums, Functional foods: bars, dairies, chocolate, beverages, Several applications have already been tested by Ingredia Nutritional. Please feel free to contact us for further information.
Chromax is a ready-to-use ingredient that will make the difference in your food supplement or functional food
29
The WHO and EFSA concluded that pure chromium is completly safe up to 250 g/day and validated Chromax complete safety
For consumer, only 2 mg/day of Chromax will provide you with all the benefits of chromium without any concern for safety
30
15
Marketing potential
Marketing potential
32
16
Stop snacking Control food craving for a successfull diet Snacking is the
first cause of failure during long-time diet. Thanks to its exclusive ingredient Chromax, which act on the carbohydrate metabolism, Stop snacking will help you get the strength to resist temptation and achieve a successful diet.
33
Conclusion
17
Conclusion
Chromax
35
Conclusion
References
Anderson, R.A. ; Bryden, N.A. ; Polansky, M.M. ; Gautschi, K. (1996). Dietary chromium effects on tissue chromium concentrations and chromium absorption in rats. The Journal of Trace Elements in Experimental Medicine ; 9 ; 11-15. Anderson, R.A. ; Cheng, N. ; Bryden, N.A. ; Polansky, M.M. ; Chi, J. ; Feng, J. (1997). Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes ; 46 ; 1786-1791. Anderson, R.A. ; Polansky, M.M. ; Bryden, N.A. (2004). Stability and absorption of chromium and absorption of chromium histidinate complexes by humans. Biological Trace Element Research ; 101 ; 211-218. Anton, S.D. ; Morrison, C.D. ; Cefalu, W.T. ; Martin, C.K. ; Coulon, S. ; Geiselman, P. ; Han, H. ; White, C.L. ; Williamson, D.A. (2008). Effects of chromium picolinate on food intake and satiety. Diabetes Technology and Therapeutics ; 10(5) ; 405-412. Bahadori, B. ; Wallner, S. ; Hacker, C. ; Boes, U. ; Komorowski, J.R. ; Wascher, T.C. (1999). Effects of chromium picolinate on insulin levels and glucose control in obese patients with type-II diabetes mellitus. Diabetes ; 48 ; A349. Cefalu, W.T. ; Bell-Farrow, A.D. ; Stegner, J. ; Wang, Z.Q. ; King, T. ; Morgan, T. ; Terry, J.G. (1999). Effect of chromium tripicolinate on insulin sensitivity in vivo. The Journal of Trace Elements in Experimental Medicine ; 12 ; 71-83.
36
18
Conclusion
References
Cheng, N. ; Zhu, X. ; Shi, H. ; Wu, W. ; Jiamin, C. ; Jianying, C. ; Anderson, R.A. (1999). Followup survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. The Journal of Trace Elements in Experimental Medicine ; 12 ; 55-60. DiSilvestro R.A. ; Dy, E. (2007). Comparison of acute absorption of commercially available chromium supplements. The Journal of Trace Elements in Medicine and Biology ; 21 ; 120-124. Docherty, J.P. ; Sack, D.A. ; Roffman, M. ; Finch, M. ; Komorowski, J.R. (2005). A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. Journal of Psychiatric Pratice ; 11(5) ; 302-314. Evans, G.W. (1989). The effect of chromium picolinate on insulin controlled parameters in humans. Int. J. Biosocial. Med. Res. ; 11 ; 163-180. Feng, J ; Lin, D. ; Zheng, A. ; Cheng, N. (2002). Chromium picolinate reduces insulin requirement in people with type 2 diabetes mellitus. Diabetes ; 51 ; A469. Ghosh, D. ; Bhattacharya, B. ; Mukherjee, B. ; Manna, B. ; Sinha, M. ; Chowdhury, J. ; Chowdhury, S. (2002). Role of chromium supplementation in Indians with type 2 diabetes mellitus. J. Nutr. Biochem. ; 13 ; 690-697. Jovanovic-Peterson, L. ; Gutlerrez, M. ; Peterson, C.M. (1999). Chromium supplementation for women with gestational diabetes mellitus. The Journal of Trace Elements in Experimental Medicine ; 12 ; 91-97. 37
Conclusion
References
Kaats, G.R. ; Blum, K. ; Fisher, J.A. ; Adelman, J.A. (1998). Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo-controlled study. Current Therapeutic Research ; 57(10) ; 747-756. Lucidi, R.S. ; Thyer, A.C. ; Easton, C.A. ; Holden, A.E.C. ; Schenken, R.S. ; Brzyski, R.G. (2005). Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. Fertil. Steril. ; 84 ; 1755-1757. Lydic, M.L. ; McNurlan, M. ; Bembo, S. ; Mitchell, L. ; Komaroff, E. ; Gelato, M. (2006). Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil. Steril. ; 86 ; 243-246. Martin, J. ; Wang, Z.Q. ; Zhang, X.H. ; Wachtel, D. ; Volaufova, J. ; Matthews, D.E. ; Cefalu, W.T. (2006). Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care ; 29(8) ; 1826-1832. Morris, B.W. ; Kouta, S. ; Robinson, R. ; MacNeil, S. ; Heller, S. (2000). Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus. Diabet. Med. ; 17 ; 684-685. Rabinovitz, H. ; Leibovitz, A. ; Madar, Z. ; Gabai, G. ; Habot, B. (2000). Blood glucose and lipid levels following chromium supplementation in diabetic elderly patients on a rehabilitation program. Gerontologist ; 40.
38
19
Conclusion
References
Ravina, A. ; Slezak, L. ; Rubal, A. ; Mirsky, N. (1995). Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. The Journal of Trace Elements in Experimental Medicine ; 8 ; 183-190. Ravina, A. ; Slezak, L. ; Mirsky, N. ; Bryden, N.A. ; Anderson, R.A. (1999). Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet. Med. ; 16 ; 164-167. Vrtovec, M. ; Vrtovec, B. ; Briski, A. ; Kocijancic, A. ; Anderson, R.A. ; Radovancevic, B. (2005). Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. American Heart Journal ; 149(4) ; 632-636. Wang, Z.Q. ; Qin, J. ; Martin, J. ; Zhang, X.H. ; Sereda, O. ; Anderson, R.A. ; Pinsonat, P. ; Cefalu, W.T. (2007). Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism ; 56 ; 1652-1655.
39
www.ingredia-nutritional.com
40
20